Kruger Stephan, Angele Martin K, Reu Simone, Sotlar Karl, Graser Anno, Haas Michael, Albertsmeier Markus, Stemmler Hans-Joachim, Heinemann Volker, Lindner Lars H, Boeck Stefan
Departments of aInternal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern bGeneral, Visceral, Transplantation, Vascular and Thoracic Surgery, Klinikum Grosshadern cClinical Radiology, Klinikum Grosshadern dDepartment of Pathology, Ludwig-Maximilians-University of Munich, Munich, Germany.
Anticancer Drugs. 2014 Aug;25(7):854-6. doi: 10.1097/CAD.0000000000000106.
Diffuse malignant peritoneal mesothelioma (DMPM) is a rare disease. Although most patients eligible for surgery undergo cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy, the role of perioperative systemic chemotherapy still remains undefined. Here we report the case of a 52-year-old female patient with advanced sarcomatoid DMPM. After five cycles of systemic pemetrexed and cisplatin, along with two cycles of regional hyperthermia, tumor resection with histomorphological examination showed a complete pathological response. We therefore conclude that there is a subgroup of DMPM patients that might benefit from systemic neoadjuvant chemotherapy with pemetrexed and cisplatin.
弥漫性恶性腹膜间皮瘤（DMPM）是一种罕见疾病。尽管大多数符合手术条件的患者会接受细胞减灭术联合腹腔内热化疗，但围手术期全身化疗的作用仍不明确。在此，我们报告一例52岁患有晚期肉瘤样DMPM的女性患者。在接受五个周期的培美曲塞和顺铂全身化疗以及两个周期的区域热疗后，经组织形态学检查的肿瘤切除显示出完全病理缓解。因此，我们得出结论，有一部分DMPM患者可能从培美曲塞和顺铂的全身新辅助化疗中获益。
